10q10k10q10k.net
Edwards Lifesciences

Edwards LifesciencesEWEarnings & Financial Report

NYSE · Health Care · Health Care Equipment

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

NextMar 19, 2026

EW Q3 2025 Key Financial Metrics

売上高

$1.6B

粗利益

$1.2B

営業利益

$307.1M

純利益

$291.1M

粗利益率

77.8%

営業利益率

19.8%

純利益率

18.7%

前年比成長

14.7%

EPS

$0.50

資金フロー

Edwards Lifesciences Q3 2025 Financial Summary

Edwards Lifesciences reported revenue of $1.6B for Q3 2025, with a net profit of $291.1M (18.7% margin). Cost of goods sold was $345.2M, operating expenses totaled $900.8M.

Key Financial Metrics

Total Revenue$1.6B
Net Profit$291.1M
Gross Margin77.8%
Operating Margin19.8%
Report PeriodQ3 2025

Edwards Lifesciences Annual Revenue by Year

Edwards Lifesciences annual revenue history includes year-by-year totals (for example, 2024 revenue was $5.7B).

YearAnnual Revenue
2024$5.7B
2023$5.7B
2022$5.4B

損益計算書

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
売上高$1.27B$1.60B$1.39B$1.35B$1.39B$1.41B$1.53B$1.55B
前年比成長-6.1%9.5%-9.4%-8.5%9.4%-11.6%10.6%14.7%

貸借対照表

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
総資産$9.36B$9.74B$10.10B$12.97B$13.06B$13.02B$13.49B$13.27B
総負債$2.64B$2.55B$2.59B$3.36B$2.99B$2.83B$2.88B$3.07B
株主資本$6.65B$7.12B$7.44B$9.55B$10.00B$10.13B$10.55B$10.21B

キャッシュフロー

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
営業CF$136.6M$-53.5M$371.5M$351.8M$-127.5M$280.4M$290.2M$573.7M